GlassScriptPhysician profile
Joseph Auble
NPI 1154028603
$1,612.94
in general payments reported to CMS, 2019-2025
17 companies · $638 in 2025
The $638 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $220 · 2024: $754 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $402.60 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $275.71 | 2025 | Lifevest |
| Lilly USA, LLC | $180.96 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $154.19 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $139.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $107.43 | 2023-2025 | Trelegy Ellipta |
| Shield Therapeutics INC | $66.36 | 2025 | |
| Pfizer INC. | $64.69 | 2023-2025 | |
| Astellas Pharma US INC | $50.33 | 2023-2025 | Veozah |
| Abbvie INC. | $37.76 | 2024 | |
| Amgen INC. | $33.82 | 2024-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $22.56 | 2024 | |
| Scpharmaceuticals INC. | $18.37 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.78 | 2025 | Eliquis |
| Mannkind Corporation | $15.17 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $14.43 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Auble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.